E-mail: info@rockypharm.hk
- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
 |
| Product Information |
Product Name: | Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH |
Synonyms: | Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH;Octa(OtBu)-Glu(ɑ-OtBu)-AEEA-AEEA-OH;11,14,20,23-Tetraoxa-2,8,17,26,31-pentaazanonatetracontanedioic acid, 3-carboxy-30-[(1,1-dimethylethoxy)carbonyl]-9,18,27,32-tetraoxo-, 49-(1,1-dimethylethyl) 1-(9H-fluoren-9-ylmethyl) ester,;22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid;Fmoc-Lys(tBu-OOC-C16-CO-Glu(AEEA-AEEA)-OtBu)-OH;11,14,20,23-Tetraoxa-2,8,17,26,31-pentaazanonatetracontanedioic acid, 3-carboxy-30-[(1,1-dimethylethoxy)carbonyl]-9,18,27,32-tetraoxo-, 49-(1,1-dimethylethyl) 1-(9H-fluoren-9-ylmethyl) ester, (3S,30S)-;Fmoc-Lys-(Octa-OtBu)-Glu(AEEA-AEEA-OH)-OH;(23S,50S)-50-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-23-(tert-butoxycarbonyl)-2,2-dimethyl-4,21,26,35,44-pentaoxo-3,30,33,39,42-pentaoxa-22,27,36,45-tetraazahenpentacontan-51-oic acid |
CAS: | 1662688-20-1 |
MF: | C64H101N5O16 |
MW: | 1196.51 |
| Fmoc-L-Lys and Its Derivatives: The Precision Foundation of Peptide Synthesis |
Fmoc-L-Lys (9-fluorenylmethyloxycarbonyl-L-lysine) serves as a cornerstone in solid-phase peptide synthesis (SPPS), while its derivatives (e.g., Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH) are invaluable in drug development and bioconjugation. This article delves into the synthesis process, stability control, and customized applications, highlighting the technical advantages and market potential of Fmoc-L-Lys derivatives.
| Core Process: Directed Synthesis and Precision Modification |
1. Synthesis Pathway of High-Complexity Derivatives
Synthesis of Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH:
Fmoc Protection:
Introducing the Fmoc group to the ε-amino of lysine ensures site-specific reaction at the α-amino position.
Side-Chain Modification:
Sequential attachment of octanoic acid (Oct), glutamic acid (Glu), and AEEA (aminoethoxyethanolamine) spacer arms with tBu protection to avoid side reactions.
Purification and Characterization:
High-purity separation via preparative HPLC and structure confirmation using LC-MS, achieving purity ≥98%.
Stability Optimization:
To ensure stability of Fmoc-L-Lys derivatives in synthesis, low-temperature storage (-20°C) under inert gas extends shelf life to 24 months.
2. Coupling Process in Solid-Phase Synthesis
Fmoc-L-Lys in SPPS:
Resin Coupling:
Using Wang resin as the carrier and HOBt/DIC as activators, the coupling efficiency exceeds 99.5%.
Deprotection Control:
Applying 20% piperidine/DMF solution for efficient removal of Fmoc within 5 minutes, ensuring residual content <0.1%.
| Quality Control: From Molecular Design to Batch Consistency |
1. Chemical Characterization
Chemical Properties of Fmoc-L-Lys Derivative:
Structural verification using NMR (1H/13C) and HRMS. The Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH CAS number and NMR spectra are provided for quality assurance.
Chiral Purity:
Ensuring enantiomeric excess (ee) ≥99.9% through chiral HPLC, preventing interference in peptide folding.
2. Production Compliance
Standards Adherence:
Complying with USP/EP guidelines, with heavy metals (Pb, As) <1 ppm and solvent residues (DMF, DCM) meeting ICH Q3C criteria.
Process Optimization:
Offering an Optimization of Fmoc-L-Lys peptide coupling report to support scale-up production.
| Application Scenarios: From Drug Development to Bioconjugation |
1. Targeted Drug Carrier Construction
Fmoc-L-Lys-Based Linker Synthesis:
Utilizing AEEA spacers to connect antibody-drug conjugates (ADCs), enhancing drug loading and stability.
Peptide Modification with Fmoc-L-Lys Derivatives:
Incorporating fluorescent labels (e.g., FITC) or PEGylation to improve in vivo half-life.
2. Innovative Therapeutics Development
Drug Candidate Synthesis:
Employing Fmoc-L-Lys for synthesizing GLP-1 analogs, antimicrobial peptides, and other clinical candidates.
Orthogonal Protection Strategy:
Using Alloc/Dde protective groups for selective modification of multiple lysine sites.
| Market Competitiveness and Customization |
1. Tailored Solutions:
Custom Synthesis of Fmoc-L-Lys Derivatives:
Flexible modification of side-chain length (number of AEEA units), protective groups (Boc, ivDde), and linker structures.
High-Purity Production:
Offering orders from gram to kilogram scale with HPLC purity ≥99%.
2. Global Supply and Technical Support:
Fmoc-L-Lys Derivative Suppliers:
ISO 9001 certified, providing COA, MSDS, and technical guidance on how to deprotect Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH.
Online Availability:
Purchase Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH online with order tracking and 48-hour dispatch.
| Product Information |
Product Name: | Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH |
Synonyms: | Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH;Octa(OtBu)-Glu(ɑ-OtBu)-AEEA-AEEA-OH;11,14,20,23-Tetraoxa-2,8,17,26,31-pentaazanonatetracontanedioic acid, 3-carboxy-30-[(1,1-dimethylethoxy)carbonyl]-9,18,27,32-tetraoxo-, 49-(1,1-dimethylethyl) 1-(9H-fluoren-9-ylmethyl) ester,;22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid;Fmoc-Lys(tBu-OOC-C16-CO-Glu(AEEA-AEEA)-OtBu)-OH;11,14,20,23-Tetraoxa-2,8,17,26,31-pentaazanonatetracontanedioic acid, 3-carboxy-30-[(1,1-dimethylethoxy)carbonyl]-9,18,27,32-tetraoxo-, 49-(1,1-dimethylethyl) 1-(9H-fluoren-9-ylmethyl) ester, (3S,30S)-;Fmoc-Lys-(Octa-OtBu)-Glu(AEEA-AEEA-OH)-OH;(23S,50S)-50-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-23-(tert-butoxycarbonyl)-2,2-dimethyl-4,21,26,35,44-pentaoxo-3,30,33,39,42-pentaoxa-22,27,36,45-tetraazahenpentacontan-51-oic acid |
CAS: | 1662688-20-1 |
MF: | C64H101N5O16 |
MW: | 1196.51 |
| Fmoc-L-Lys and Its Derivatives: The Precision Foundation of Peptide Synthesis |
Fmoc-L-Lys (9-fluorenylmethyloxycarbonyl-L-lysine) serves as a cornerstone in solid-phase peptide synthesis (SPPS), while its derivatives (e.g., Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH) are invaluable in drug development and bioconjugation. This article delves into the synthesis process, stability control, and customized applications, highlighting the technical advantages and market potential of Fmoc-L-Lys derivatives.
| Core Process: Directed Synthesis and Precision Modification |
1. Synthesis Pathway of High-Complexity Derivatives
Synthesis of Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH:
Fmoc Protection:
Introducing the Fmoc group to the ε-amino of lysine ensures site-specific reaction at the α-amino position.
Side-Chain Modification:
Sequential attachment of octanoic acid (Oct), glutamic acid (Glu), and AEEA (aminoethoxyethanolamine) spacer arms with tBu protection to avoid side reactions.
Purification and Characterization:
High-purity separation via preparative HPLC and structure confirmation using LC-MS, achieving purity ≥98%.
Stability Optimization:
To ensure stability of Fmoc-L-Lys derivatives in synthesis, low-temperature storage (-20°C) under inert gas extends shelf life to 24 months.
2. Coupling Process in Solid-Phase Synthesis
Fmoc-L-Lys in SPPS:
Resin Coupling:
Using Wang resin as the carrier and HOBt/DIC as activators, the coupling efficiency exceeds 99.5%.
Deprotection Control:
Applying 20% piperidine/DMF solution for efficient removal of Fmoc within 5 minutes, ensuring residual content <0.1%.
| Quality Control: From Molecular Design to Batch Consistency |
1. Chemical Characterization
Chemical Properties of Fmoc-L-Lys Derivative:
Structural verification using NMR (1H/13C) and HRMS. The Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH CAS number and NMR spectra are provided for quality assurance.
Chiral Purity:
Ensuring enantiomeric excess (ee) ≥99.9% through chiral HPLC, preventing interference in peptide folding.
2. Production Compliance
Standards Adherence:
Complying with USP/EP guidelines, with heavy metals (Pb, As) <1 ppm and solvent residues (DMF, DCM) meeting ICH Q3C criteria.
Process Optimization:
Offering an Optimization of Fmoc-L-Lys peptide coupling report to support scale-up production.
| Application Scenarios: From Drug Development to Bioconjugation |
1. Targeted Drug Carrier Construction
Fmoc-L-Lys-Based Linker Synthesis:
Utilizing AEEA spacers to connect antibody-drug conjugates (ADCs), enhancing drug loading and stability.
Peptide Modification with Fmoc-L-Lys Derivatives:
Incorporating fluorescent labels (e.g., FITC) or PEGylation to improve in vivo half-life.
2. Innovative Therapeutics Development
Drug Candidate Synthesis:
Employing Fmoc-L-Lys for synthesizing GLP-1 analogs, antimicrobial peptides, and other clinical candidates.
Orthogonal Protection Strategy:
Using Alloc/Dde protective groups for selective modification of multiple lysine sites.
| Market Competitiveness and Customization |
1. Tailored Solutions:
Custom Synthesis of Fmoc-L-Lys Derivatives:
Flexible modification of side-chain length (number of AEEA units), protective groups (Boc, ivDde), and linker structures.
High-Purity Production:
Offering orders from gram to kilogram scale with HPLC purity ≥99%.
2. Global Supply and Technical Support:
Fmoc-L-Lys Derivative Suppliers:
ISO 9001 certified, providing COA, MSDS, and technical guidance on how to deprotect Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH.
Online Availability:
Purchase Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH online with order tracking and 48-hour dispatch.
